experimentation (Ghose, 1987; Ghose et al., 1999).

2.2.4.  Leadlikeness
According to Teague et al. (1999) compounds with MW in the range 250–350, a XLOGP3 value of <3.5 and <7 rotatable bonds satisfy the criteria for leadlikeness.

2.2.5.  Egan rule
It is defined as compounds having TPSA > 131.6 Å or log p > 5.88 have drug-like